Skip to main content
Top
Published in: Acta Diabetologica 12/2018

01-12-2018 | Original Article

C1q/TNF-related protein-6 is associated with insulin resistance and the development of diabetes in Chinese population

Authors: Miao Wang, Xuejiao Tang, Ling Li, Dongfang Liu, Hua Liu, Hongting Zheng, Wuquan Deng, Xili Zhao, Gangyi Yang

Published in: Acta Diabetologica | Issue 12/2018

Login to get access

Abstract

Aims

C1q/tumor necrosis factor-related protein-6 (CTRP6) is a novel adipokine and has emerged as an important mediator for lipid and glucose metabolism. However, to date, the relationship between CTRP6 and T2DM in humans has not been demonstrated. Our objective is to investigate the association of circulating CTRP6 with T2DM in a cross-sectional study.

Methods

118 patients with newly diagnosed T2DM, 98 subjects with impaired glucose tolerant (IGT) and 132 healthy subjects were recruited for this study. OGTT were performed in 48 healthy individuals to investigate the association of CTRP6 with glucose, insulin and other adipokines. Circulating CTRP6, TNF-α and Adipoq were measured by ELISA.

Results

IGT and T2DM individuals had higher serum CTRP6 levels than healthy controls (406.2 ± 136.6 and 539.1 ± 169.7 vs. 354.3 ± 117.2 ng/mL; both P < 0.01), whereas serum CTRP6 concentrations were further increased in T2DM patients compared with IGT individuals (P < 0.01). Serum CTRP6 levels were found to be related positively to BMI, WHR, FAT%, TC, TG, HbA1c, FBG, 2 h-OGTT, fasting insulin (FIns), 2 h-Ins, HOMA-IR and TNF-α, and negatively with HDL-C and Adipoq in all individuals (P < 0.05 or P < 0.01). Multivariate logistic regression analysis demonstrated that CTRP6 was correlated with both IGT and T2DM. After an oral glucose challenge, serum CTRP6 concentrations exhibited a similar change with blood glucose, insulin, TNF-α and Adipoq.

Conclusions

CTRP6 may be a metabolism- and nutrition-related adipokine and may be related to insulin resistance and T2DM.

Trial registrations

Clinical Trial Registration Number: ChiCTR-OCC-11001422. Registration name: Plasma cytokines and endothelial function in type 2 diabetes
Literature
1.
go back to reference Luo L, Liu M (2016) Adipose tissue in control of metabolism. J Endocrinol 231(3):R77–R99CrossRef Luo L, Liu M (2016) Adipose tissue in control of metabolism. J Endocrinol 231(3):R77–R99CrossRef
2.
go back to reference Liao WL, Lee WJ, Chen CC et al (2017) Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes. Oncotarge 8(11):18050–18058CrossRef Liao WL, Lee WJ, Chen CC et al (2017) Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes. Oncotarge 8(11):18050–18058CrossRef
3.
go back to reference Rasouli N, Kern PA (2008) Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93(1):64–73CrossRef Rasouli N, Kern PA (2008) Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93(1):64–73CrossRef
4.
go back to reference Maury E, Brichard SM (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314(1):1–16CrossRef Maury E, Brichard SM (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314(1):1–16CrossRef
5.
go back to reference Polyzos SA, Kountouras J, Mantzoros CS (2016) Adipokines in nonalcoholic fatty liver disease. Metabolism 65(8):1062–1079CrossRef Polyzos SA, Kountouras J, Mantzoros CS (2016) Adipokines in nonalcoholic fatty liver disease. Metabolism 65(8):1062–1079CrossRef
6.
go back to reference Lau WB, Ohashi K, Wang Y, Ogawa H, Murohara T, Ma XL et al (2017) Role of adipokines in cardiovascular disease. Circ J 81(7):920–928CrossRef Lau WB, Ohashi K, Wang Y, Ogawa H, Murohara T, Ma XL et al (2017) Role of adipokines in cardiovascular disease. Circ J 81(7):920–928CrossRef
8.
go back to reference Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish HF (2008) Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-γagonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 416(2):161–177CrossRef Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish HF (2008) Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-γagonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 416(2):161–177CrossRef
9.
go back to reference Seldin MM, Tan SY, Wong GW (2014) Metabolic function of the CTRP family of hormones. Rev Endocr Metab Disord 15(2):111–123CrossRef Seldin MM, Tan SY, Wong GW (2014) Metabolic function of the CTRP family of hormones. Rev Endocr Metab Disord 15(2):111–123CrossRef
10.
go back to reference Zheng Q, Yuan Y, Yi W et al (2011) C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway. Arterioscler Thromb Vasc Biol 31(11):2616–2623CrossRef Zheng Q, Yuan Y, Yi W et al (2011) C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway. Arterioscler Thromb Vasc Biol 31(11):2616–2623CrossRef
11.
go back to reference Lei H, Wu D, Wang JY et al (2015) C1q/tumor necrosis factor-related protein-6 attenuates post-infarct cardiac fibrosis by targeting RhoA/MRTF-A pathway and inhibiting myofibroblast differentiation. Basic Res Cardiol 110(4):35CrossRef Lei H, Wu D, Wang JY et al (2015) C1q/tumor necrosis factor-related protein-6 attenuates post-infarct cardiac fibrosis by targeting RhoA/MRTF-A pathway and inhibiting myofibroblast differentiation. Basic Res Cardiol 110(4):35CrossRef
12.
go back to reference Chi L, Hu X, Zhang W et al (2017) Adipokine CTRP6 improves PPARγ activation to alleviate angiotensin II-induced hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats. Biochem Biophys Res Commun 482(4):727–734CrossRef Chi L, Hu X, Zhang W et al (2017) Adipokine CTRP6 improves PPARγ activation to alleviate angiotensin II-induced hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats. Biochem Biophys Res Commun 482(4):727–734CrossRef
13.
go back to reference Wu W, Sun Y, Zhao C et al (2016) Lipogenesis in myoblasts and its regulation of CTRP6 by AdipoR1/Erk/PPARγ signaling pathway. Acta Biochim Biophys Sin (Shanghai) 48(6):509–519CrossRef Wu W, Sun Y, Zhao C et al (2016) Lipogenesis in myoblasts and its regulation of CTRP6 by AdipoR1/Erk/PPARγ signaling pathway. Acta Biochim Biophys Sin (Shanghai) 48(6):509–519CrossRef
14.
go back to reference Wu W, Zhang J, Zhao C, Sun Y, Pang W, Yang G (2017) CTRP6 regulates porcine adipocyte proliferation and differentiation by the AdipoR1/MAPK signaling pathway. J Agric Food Chem 65(27):5512–5522CrossRef Wu W, Zhang J, Zhao C, Sun Y, Pang W, Yang G (2017) CTRP6 regulates porcine adipocyte proliferation and differentiation by the AdipoR1/MAPK signaling pathway. J Agric Food Chem 65(27):5512–5522CrossRef
15.
go back to reference Wu WJ, Mo DL, Zhao CZ et al (2015) Knockdown of CTRP6 inhibits adipogenesis via lipogenic marker genes and Erk1/2 signalling pathway. Cell Biol Int 39(5):554–562CrossRef Wu WJ, Mo DL, Zhao CZ et al (2015) Knockdown of CTRP6 inhibits adipogenesis via lipogenic marker genes and Erk1/2 signalling pathway. Cell Biol Int 39(5):554–562CrossRef
16.
go back to reference Fan RH, Zhu XM, Sun YW, Peng HZ, Wu HL, Gao WJ (2016) CTRP6 inhibits fibrogenesis in TGF-β1-stimulated human dermal fibroblasts. Biochem Biophys Res Commun 475(4):356–360CrossRef Fan RH, Zhu XM, Sun YW, Peng HZ, Wu HL, Gao WJ (2016) CTRP6 inhibits fibrogenesis in TGF-β1-stimulated human dermal fibroblasts. Biochem Biophys Res Commun 475(4):356–360CrossRef
17.
go back to reference Murayama MA, Kakuta S, Inoue A et al (2015) CTRP6 is an endogenous complement regulator that can effectively treat induced arthritis. Nat Commun 6:8483CrossRef Murayama MA, Kakuta S, Inoue A et al (2015) CTRP6 is an endogenous complement regulator that can effectively treat induced arthritis. Nat Commun 6:8483CrossRef
18.
go back to reference Cooper JD, Smyth DJ, Smiles AM et al (2008) Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 40(12):1399–1401CrossRef Cooper JD, Smyth DJ, Smiles AM et al (2008) Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 40(12):1399–1401CrossRef
19.
go back to reference Lei X, Seldin MM, Little HC, Choy N, Klonisch T, Wong GW (2017) C1q/TNF-related protein 6 (CTRP6) links obesity to adipose tissue inflammation and insulin resistance. J Biol Chem 292(36):14836–14850CrossRef Lei X, Seldin MM, Little HC, Choy N, Klonisch T, Wong GW (2017) C1q/TNF-related protein 6 (CTRP6) links obesity to adipose tissue inflammation and insulin resistance. J Biol Chem 292(36):14836–14850CrossRef
20.
go back to reference Lee W, Kim MJ, Park EJ, Choi YJ, Park SY (2010) C1qTNF-related protein-6 mediates fatty acid oxidation via the activation of the AMP-activated protein kinase. FEBS Lett 584(5):968–972CrossRef Lee W, Kim MJ, Park EJ, Choi YJ, Park SY (2010) C1qTNF-related protein-6 mediates fatty acid oxidation via the activation of the AMP-activated protein kinase. FEBS Lett 584(5):968–972CrossRef
21.
go back to reference American Diabetes A (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1):S62–S69CrossRef American Diabetes A (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1):S62–S69CrossRef
22.
go back to reference Li K, Xu X, Hu W et al (2014) Glypican-4 is increased in human subjects with impaired glucose tolerance and decreased in patients with newly diagnosed type 2 diabetes. Acta Diabetol 51(6):981–990CrossRef Li K, Xu X, Hu W et al (2014) Glypican-4 is increased in human subjects with impaired glucose tolerance and decreased in patients with newly diagnosed type 2 diabetes. Acta Diabetol 51(6):981–990CrossRef
23.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRef
24.
go back to reference Li L, Miao Z, Liu R, Yang M, Liu H, Yang G (2011) 11 Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med 17(11–12):1168–1178PubMedPubMedCentral Li L, Miao Z, Liu R, Yang M, Liu H, Yang G (2011) 11 Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med 17(11–12):1168–1178PubMedPubMedCentral
25.
go back to reference Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14(6):561–566CrossRef Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14(6):561–566CrossRef
26.
go back to reference Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Investig 116(7):1784–1792CrossRef Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Investig 116(7):1784–1792CrossRef
27.
go back to reference Yang M, Liu R, Li S et al (2013) Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 36(5):1074–1082CrossRef Yang M, Liu R, Li S et al (2013) Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 36(5):1074–1082CrossRef
28.
go back to reference Hu W, Li L, Yang M et al (2013) Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab 98(1):290–298CrossRef Hu W, Li L, Yang M et al (2013) Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab 98(1):290–298CrossRef
29.
go back to reference Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85–97CrossRef Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85–97CrossRef
30.
go back to reference Kim MJ, Lee W, Park EJ, Park SY (2010) C1qTNF-related protein-6 increases the expression of interleukin-10 in macrophages. Mol Cells 30(1):59–64CrossRef Kim MJ, Lee W, Park EJ, Park SY (2010) C1qTNF-related protein-6 increases the expression of interleukin-10 in macrophages. Mol Cells 30(1):59–64CrossRef
Metadata
Title
C1q/TNF-related protein-6 is associated with insulin resistance and the development of diabetes in Chinese population
Authors
Miao Wang
Xuejiao Tang
Ling Li
Dongfang Liu
Hua Liu
Hongting Zheng
Wuquan Deng
Xili Zhao
Gangyi Yang
Publication date
01-12-2018
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 12/2018
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-018-1203-2

Other articles of this Issue 12/2018

Acta Diabetologica 12/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.